BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamaga LYI, Cunha ML, Campos Neto GC, Garcia MRT, Yang JH, Camacho CP, Wagner J, Funari MBG. 68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging 2017;44:1695-701. [PMID: 28429044 DOI: 10.1007/s00259-017-3701-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Ross J, Parmar HA, Avram A, Ibrahim M, Mukherji SK. Imaging in Thyroid Cancer. Oncologic Imaging : a Multidisciplinary Approach 2023. [DOI: 10.1016/b978-0-323-69538-1.00036-7] [Reference Citation Analysis]
2 Boekestijn I, van Oosterom MN, Dell'Oglio P, van Velden FHP, Pool M, Maurer T, Rietbergen DDD, Buckle T, van Leeuwen FWB. The current status and future prospects for molecular imaging-guided precision surgery. Cancer Imaging 2022;22:48. [PMID: 36068619 DOI: 10.1186/s40644-022-00482-2] [Reference Citation Analysis]
3 Wüstemann J, Eilsberger F, Petersen M, Kreißl MC. Nuklearmedizinische Diagnostik des medullären Schilddrüsenkarzinoms. Onkologie 2022;28:679-686. [DOI: 10.1007/s00761-022-01206-8] [Reference Citation Analysis]
4 Schlumberger M, Garcia C, Hadoux J, Klain M, Lamartina L. Functional imaging in thyroid cancer patients with metastases and therapeutic implications. Presse Med 2022;51:104113. [PMID: 35131318 DOI: 10.1016/j.lpm.2022.104113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Trofimiuk-müldner M, Domagała B, Hubalewska-dydejczyk A. Medullary Thyroid Cancer. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00106-x] [Reference Citation Analysis]
6 Imperiale A, Leroy-freschini B, Taieb D. PET in medullary thyroid carcinoma. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00027-2] [Reference Citation Analysis]
7 Klain M, Hadoux J, Nappi C, Finessi M, Ambrosio R, Schlumberger M, Cuocolo A, Deandreis D, Salvatore D. Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives. Endocrine 2021. [PMID: 34748168 DOI: 10.1007/s12020-021-02930-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Galgano SJ, Wei B, Rose JB. PET Imaging of Neuroendocrine Tumors. Radiol Clin North Am 2021;59:789-99. [PMID: 34392919 DOI: 10.1016/j.rcl.2021.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pandey S, Malviya G, Chottova Dvorakova M. Role of Peptides in Diagnostics. Int J Mol Sci 2021;22:8828. [PMID: 34445532 DOI: 10.3390/ijms22168828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Asa S, Sonmezoglu K, Uslu-Besli L, Sahin OE, Karayel E, Pehlivanoglu H, Sager S, Kabasakal L, Ocak M, Sayman HB. Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT. Ann Nucl Med 2021;35:900-15. [PMID: 33993425 DOI: 10.1007/s12149-021-01627-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
11 Fu H, Sa R, Cheng L, Jin Y, Qiu X, Liu M, Chen L. Updated Review of Nuclear Molecular Imaging of Thyroid Cancers. Endocr Pract 2021;27:494-502. [PMID: 33934754 DOI: 10.1016/j.eprac.2020.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Saponjski J, Macut D, Saranovic DS, Radovic B, Artiko V. Clinical relevance of 18F-FDG PET/CT in the postoperative follow-up of patients with history of medullary thyroid cancer. Radiol Oncol 2020;55:18-25. [PMID: 33885241 DOI: 10.2478/raon-2020-0069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Marcus C, Subramaniam RM. Role of Non-FDG-PET/CT in Head and Neck Cancer. Semin Nucl Med 2021;51:68-78. [PMID: 33246541 DOI: 10.1053/j.semnuclmed.2020.07.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
14 Wang X, Huo L. Non-18F-Fluorodeoxyglucos PET Tracers in Pediatric Disease. PET Clinics 2020;15:241-251. [DOI: 10.1016/j.cpet.2020.03.013] [Reference Citation Analysis]
15 Tuncel M, Kılıçkap S, Süslü N. Clinical impact of 68Ga-DOTATATE PET-CT imaging in patients with medullary thyroid cancer. Ann Nucl Med 2020;34:663-74. [PMID: 32602032 DOI: 10.1007/s12149-020-01494-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
16 Brown SJ, Waguespack SG, Chuang HH, Murphy WA, Hu MI. “Detecting the Undetectable”. Clinical Thyroidology 2020;32:39-42. [DOI: 10.1089/ct.2020;32.39-42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Terroir M, Caramella C, Borget I, Bidault S, Dromain C, El Farsaoui K, Deandreis D, Grimaldi S, Lumbroso J, Berdelou A, Hadoux J, Hescot S, Hartl D, Baudin E, Schlumberger M, Leboulleux S. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients. Thyroid 2019;29:1457-64. [DOI: 10.1089/thy.2018.0351] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
18 Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2020;47:61-77. [DOI: 10.1007/s00259-019-04458-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 11.8] [Reference Citation Analysis]
19 Werner RA, Thackeray JT, Pomper MG, Bengel FM, Gorin MA, Derlin T, Rowe SP. Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J Clin Med 2019;8:E1060. [PMID: 31331016 DOI: 10.3390/jcm8071060] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
20 Kushchayev SV, Kushchayeva YS, Tella SH, Glushko T, Pacak K, Teytelboym OM. Medullary Thyroid Carcinoma: An Update on Imaging. J Thyroid Res 2019;2019:1893047. [PMID: 31360432 DOI: 10.1155/2019/1893047] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
21 Hoang JK, Oldan JD, Mandel SJ, Policeni B, Agarwal V, Burns J, Bykowski J, Harvey HB, Juliano AF, Kennedy TA, Moonis G, Pannell JS, Parsons MS, Schroeder JW, Subramaniam RM, Whitehead MT, Corey AS. ACR Appropriateness Criteria® Thyroid Disease. Journal of the American College of Radiology 2019;16:S300-14. [DOI: 10.1016/j.jacr.2019.02.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
22 Tiwari R, Singh AK, Somwaru AS, Menias CO, Prasad SR, Katabathina VS. Radiologist’s Primer on Imaging of Common Hereditary Cancer Syndromes. RadioGraphics 2019;39:759-78. [DOI: 10.1148/rg.2019180171] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
23 Shahbazi-Gahrouei D, Moradi Khaniabadi P, Moradi Khaniabadi B, Shahbazi-Gahrouei S. Medical imaging modalities using nanoprobes for cancer diagnosis: A literature review on recent findings. J Res Med Sci 2019;24:38. [PMID: 31143239 DOI: 10.4103/jrms.JRMS_437_18] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
24 Choudhary G, Galgano S. Somatostatin Receptor Positron Emission Tomography: Beyond Gastroenteropancreatic Neuroendocrine Tumors. Curr Radiol Rep 2019;7. [DOI: 10.1007/s40134-019-0322-z] [Reference Citation Analysis]
25 Souteiro P, Gouveia P, Ferreira G, Belo S, Costa C, Carvalho D, Duarte H, Sampaio IL. 68Ga-DOTANOC and 18F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers. Endocrine 2019;64:322-9. [PMID: 30684230 DOI: 10.1007/s12020-019-01846-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
26 Singh S, Poon R, Wong R, Metser U. 68Ga PET Imaging in Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis. Clin Nucl Med 2018;43:802-10. [DOI: 10.1097/rlu.0000000000002276] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
27 Bi Y, Ren X, Bai X, Meng Y, Luo Y, Cao J, Zhang Y, Liang Z. PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population. Eur J Surg Oncol 2019;45:353-8. [PMID: 30528043 DOI: 10.1016/j.ejso.2018.10.060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
28 Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Higuchi T, Weich A, Sheikhbahaei S, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP. Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Ann Nucl Med 2018;32:512-22. [PMID: 30109562 DOI: 10.1007/s12149-018-1291-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
29 Asati S, Pandey V, Soni V. RGD Peptide as a Targeting Moiety for Theranostic Purpose: An Update Study. Int J Pept Res Ther 2019;25:49-65. [DOI: 10.1007/s10989-018-9728-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
30 Elisei R, Matrone A. Medullary Thyroid Cancer: Diagnosis and Non Surgical Management. Practical Management of Thyroid Cancer 2018. [DOI: 10.1007/978-3-319-91725-2_19] [Reference Citation Analysis]
31 Schütz F, Lautenschläger C, Lorenz K, Haerting J. Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis. Eur Thyroid J 2018;7:13-20. [PMID: 29594049 DOI: 10.1159/000481707] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
32 Fernandes RS, de Aguiar Ferreira C, Soares DCF, Maffione AM, Townsend DM, Rubello D, de Barros ALB. The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review. Biomed Pharmacother 2017;95:469-76. [PMID: 28865367 DOI: 10.1016/j.biopha.2017.08.079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
33 Maffione AM, Giammarile F, Rubello D. SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction? Eur J Nucl Med Mol Imaging 2017;44:1692-4. [PMID: 28638977 DOI: 10.1007/s00259-017-3757-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]